Celldex Therapeutics, Inc. (CLDX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 06, 2025

$26.58

P/E Ratio

N/A

Market Cap

$1.76B

Loading...
Description

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Metrics

Overview

  • HQHampton, NJ
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerCLDX
  • Price$26.58-0.86%

Trading Information

  • Market cap$1.76B
  • Float97.52%
  • Average Daily Volume (1m)967,066
  • Average Daily Volume (3m)983,690
  • EPS-$2.57

Company

  • Revenue$9.98M
  • Rev growth (1yr)110.35%
  • Net income-$42.12M
  • Gross margin75.37%
  • EBITDA margin-1,608.90%
  • EBITDA-$51.34M
  • EV$1.51B
  • EV/Revenue150.93
  • P/EN/A
  • P/S176.63
  • P/B2.24
Documents